File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: OIC-A006 promotes osteogenesis in vitro and in vivo
  • Basic View
  • Metadata View
  • XML View
TitleOIC-A006 promotes osteogenesis in vitro and in vivo
 
AuthorsCai, M2
Liu, X2
Shao, J2
Qi, J2
Wang, J2
Zhu, Y2
Zhou, Q2
Wang, J2
Zhao, Q2
Li, G2
Liang, J2
Lu, WW1
Deng, L2
 
Issue Date2008
 
PublisherGovi Verlag Pharmazeutischer Verlag GmbH. The Journal's web site is located at http://www.govi.de/pharmazie.htm
 
CitationPharmazie, 2008, v. 63 n. 10, p. 751-756 [How to Cite?]
DOI: http://dx.doi.org/10.1691/ph.2008.8559
 
AbstractBone morphogenesis proteins (BMPs) are one of the potent bone-forming factors. However, the safety, utility, and cost effectiveness of BMPs must be considered. Nowadays, there has been substantial interest in developing a chemical compound that safely promotes bone formation and facilitates fracture repair. Based on previous research with high throughout screening assay, we found one potent osteogenic inductive compound, named as OIC-A006 (Osteogenic inducible compound-active 006), which is classified in the amine family. In this study, we aimed to investigate the inducing effects of OIC-A006 on osteogenesis by bone marrow stem cells (BMSCs) in vitro and in vivo. We demonstrated that OIC-A006, at different concentrations, especially at optimal concentration of 6.25 μM, could stimulate BMSCs to express alkaline phosphatase (ALP), core-binding factor a1 (Cbfa1), osteopontin (OPN) and osteocalcin (OC), and to form calcified nodules in vitro. Under the bone tissue culture conditions, OIC-A006 also stimulated new bone formation of murine calvarial and metatarsal bone, indicating that OIC-A006 may exert positive effects on osteogenesis. Furthermore, to elucidate the in vivo osteogenic potential of OIC-A006, we used a rabbit skull defect model treated with sustained release microcapsules (OIC-A006/PLGA-MC) injected s.c. adjacent to the defect. These results revealed, for the first time, that OIC-A006 has the potential to promote osteogenesis in vitro and in vivo. This new compound may provide a new alterative agent for growth factors to promote bone healing and bone regeneration.
 
ISSN0031-7144
2013 Impact Factor: 1.003
2013 SCImago Journal Rankings: 0.361
 
DOIhttp://dx.doi.org/10.1691/ph.2008.8559
 
ISI Accession Number IDWOS:000260021800011
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorCai, M
 
dc.contributor.authorLiu, X
 
dc.contributor.authorShao, J
 
dc.contributor.authorQi, J
 
dc.contributor.authorWang, J
 
dc.contributor.authorZhu, Y
 
dc.contributor.authorZhou, Q
 
dc.contributor.authorWang, J
 
dc.contributor.authorZhao, Q
 
dc.contributor.authorLi, G
 
dc.contributor.authorLiang, J
 
dc.contributor.authorLu, WW
 
dc.contributor.authorDeng, L
 
dc.date.accessioned2010-05-31T03:51:14Z
 
dc.date.available2010-05-31T03:51:14Z
 
dc.date.issued2008
 
dc.description.abstractBone morphogenesis proteins (BMPs) are one of the potent bone-forming factors. However, the safety, utility, and cost effectiveness of BMPs must be considered. Nowadays, there has been substantial interest in developing a chemical compound that safely promotes bone formation and facilitates fracture repair. Based on previous research with high throughout screening assay, we found one potent osteogenic inductive compound, named as OIC-A006 (Osteogenic inducible compound-active 006), which is classified in the amine family. In this study, we aimed to investigate the inducing effects of OIC-A006 on osteogenesis by bone marrow stem cells (BMSCs) in vitro and in vivo. We demonstrated that OIC-A006, at different concentrations, especially at optimal concentration of 6.25 μM, could stimulate BMSCs to express alkaline phosphatase (ALP), core-binding factor a1 (Cbfa1), osteopontin (OPN) and osteocalcin (OC), and to form calcified nodules in vitro. Under the bone tissue culture conditions, OIC-A006 also stimulated new bone formation of murine calvarial and metatarsal bone, indicating that OIC-A006 may exert positive effects on osteogenesis. Furthermore, to elucidate the in vivo osteogenic potential of OIC-A006, we used a rabbit skull defect model treated with sustained release microcapsules (OIC-A006/PLGA-MC) injected s.c. adjacent to the defect. These results revealed, for the first time, that OIC-A006 has the potential to promote osteogenesis in vitro and in vivo. This new compound may provide a new alterative agent for growth factors to promote bone healing and bone regeneration.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationPharmazie, 2008, v. 63 n. 10, p. 751-756 [How to Cite?]
DOI: http://dx.doi.org/10.1691/ph.2008.8559
 
dc.identifier.doihttp://dx.doi.org/10.1691/ph.2008.8559
 
dc.identifier.epage756
 
dc.identifier.hkuros166630
 
dc.identifier.isiWOS:000260021800011
 
dc.identifier.issn0031-7144
2013 Impact Factor: 1.003
2013 SCImago Journal Rankings: 0.361
 
dc.identifier.issue10
 
dc.identifier.pmid18972839
 
dc.identifier.scopuseid_2-s2.0-54149114730
 
dc.identifier.spage751
 
dc.identifier.urihttp://hdl.handle.net/10722/59490
 
dc.identifier.volume63
 
dc.languageeng
 
dc.publisherGovi Verlag Pharmazeutischer Verlag GmbH. The Journal's web site is located at http://www.govi.de/pharmazie.htm
 
dc.publisher.placeGermany
 
dc.relation.ispartofPharmazie
 
dc.relation.referencesReferences in Scopus
 
dc.titleOIC-A006 promotes osteogenesis in vitro and in vivo
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Cai, M</contributor.author>
<contributor.author>Liu, X</contributor.author>
<contributor.author>Shao, J</contributor.author>
<contributor.author>Qi, J</contributor.author>
<contributor.author>Wang, J</contributor.author>
<contributor.author>Zhu, Y</contributor.author>
<contributor.author>Zhou, Q</contributor.author>
<contributor.author>Wang, J</contributor.author>
<contributor.author>Zhao, Q</contributor.author>
<contributor.author>Li, G</contributor.author>
<contributor.author>Liang, J</contributor.author>
<contributor.author>Lu, WW</contributor.author>
<contributor.author>Deng, L</contributor.author>
<date.accessioned>2010-05-31T03:51:14Z</date.accessioned>
<date.available>2010-05-31T03:51:14Z</date.available>
<date.issued>2008</date.issued>
<identifier.citation>Pharmazie, 2008, v. 63 n. 10, p. 751-756</identifier.citation>
<identifier.issn>0031-7144</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/59490</identifier.uri>
<description.abstract>Bone morphogenesis proteins (BMPs) are one of the potent bone-forming factors. However, the safety, utility, and cost effectiveness of BMPs must be considered. Nowadays, there has been substantial interest in developing a chemical compound that safely promotes bone formation and facilitates fracture repair. Based on previous research with high throughout screening assay, we found one potent osteogenic inductive compound, named as OIC-A006 (Osteogenic inducible compound-active 006), which is classified in the amine family. In this study, we aimed to investigate the inducing effects of OIC-A006 on osteogenesis by bone marrow stem cells (BMSCs) in vitro and in vivo. We demonstrated that OIC-A006, at different concentrations, especially at optimal concentration of 6.25 &#956;M, could stimulate BMSCs to express alkaline phosphatase (ALP), core-binding factor a1 (Cbfa1), osteopontin (OPN) and osteocalcin (OC), and to form calcified nodules in vitro. Under the bone tissue culture conditions, OIC-A006 also stimulated new bone formation of murine calvarial and metatarsal bone, indicating that OIC-A006 may exert positive effects on osteogenesis. Furthermore, to elucidate the in vivo osteogenic potential of OIC-A006, we used a rabbit skull defect model treated with sustained release microcapsules (OIC-A006/PLGA-MC) injected s.c. adjacent to the defect. These results revealed, for the first time, that OIC-A006 has the potential to promote osteogenesis in vitro and in vivo. This new compound may provide a new alterative agent for growth factors to promote bone healing and bone regeneration.</description.abstract>
<language>eng</language>
<publisher>Govi Verlag Pharmazeutischer Verlag GmbH. The Journal&apos;s web site is located at http://www.govi.de/pharmazie.htm</publisher>
<relation.ispartof>Pharmazie</relation.ispartof>
<title>OIC-A006 promotes osteogenesis in vitro and in vivo</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1691/ph.2008.8559</identifier.doi>
<identifier.pmid>18972839</identifier.pmid>
<identifier.scopus>eid_2-s2.0-54149114730</identifier.scopus>
<identifier.hkuros>166630</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-54149114730&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>63</identifier.volume>
<identifier.issue>10</identifier.issue>
<identifier.spage>751</identifier.spage>
<identifier.epage>756</identifier.epage>
<identifier.isi>WOS:000260021800011</identifier.isi>
<publisher.place>Germany</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Shanghai Jiaotong University